Latest news with #TheNasdaqCapitalMarket
Business Insider
2 days ago
- Business
- Business Insider
BloomZ granted 180-day extension by Nasdaq to regain compliance
BloomZ (BLMZ) announced it has received a letter form the Nasdaq Listing Qualification Staff granting it a second 180 calendar day period, or until December 1, 2025, to regain compliance with the minimum $1.00 per share bid price requirement for continued listing on The Nasdaq Capital Market, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(ii). The company was initially notified on December 2, 2024, that it did not meet the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), and was provided 180 calendar days, or until June 2, 2025, to regain compliance. As the company was not able to regain compliance during the first compliance period, the Staff has determined that the company is eligible for an additional 180-day period to regain compliance. Confident Investing Starts Here:
Miami Herald
29-05-2025
- Business
- Miami Herald
Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025
STONY BROOK, NY / ACCESS Newswire / May 29, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it will effect a 1-for-15 reverse stock split of its issued and outstanding common stock. The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on June 2, 2025, and Applied DNA common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market (the "Nasdaq") as of the commencement of market open that same day. Applied DNA common stock will continue to trade on The Nasdaq Capital Market under the symbol "APDN" following the reverse stock split, with a new CUSIP number of 03815U607. The CUSIP number for the Company's book entry warrants will not change. After the effectiveness of the reverse stock split, the number of outstanding shares of common stock will be reduced from approximately 7.8 million (as of the date of this press release) to approximately 519 thousand. The total authorized number of shares will not be reduced. Proportional adjustments will be made to the number of shares of common stock issuable upon exercise or vesting of the Company's outstanding stock options, restricted stock units, and warrants, as well as the applicable exercise or conversion prices, and to the number of shares issuable under the Company's equity incentive plans and other existing agreements. No fractional shares will be issued in connection with the reverse stock split, and fractional shares resulting from the reverse stock split will be rounded up to the nearest whole share. There will be no change in the par value of $0.001 per share of the common stock as a result of the reverse stock split. As previously disclosed, at an annual meeting of stockholders held on May 22, 2025, the Company's stockholders voted to approve a proposal granting the Company's Board of Directors the discretion to amend the Company's certificate of incorporation to effect a reverse stock split of the Company's common stock at a ratio in the range from one-for-five to one-for-fifty. The Company's Board of Directors approved a 1-for-15 reverse stock split on May 27, 2025. The reverse stock split is primarily intended to bring the Company into compliance with the $1.00 minimum bid price requirement for maintaining its listing on Nasdaq. There is no guarantee that the Company will meet the minimum bid price requirement, and even if it does, there is no guarantee that it will be able to meet all additional requirements for continued listing on Nasdaq. Applied DNA's transfer agent, Equiniti Trust Company, will provide information to stockholders regarding their stock ownership following the reverse stock split. Stockholders holding their shares in book-entry form or through a bank, broker, or other nominee do not need to take any action in connection with the reverse stock split. Their accounts will be automatically adjusted to reflect the number of shares owned. Beneficial holders are encouraged to contact their bank, broker, or other nominee with any procedural questions. About Applied DNA Sciences Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in two business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; and (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services. Visit for more information. Follow us on X and LinkedIn. Forward-Looking Statements The statements made by Applied DNA in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. These forward-looking statements are based largely on the Company's expectations and projections about future events and future trends affecting our business and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including statements regarding the effective date of the reverse stock split and the trading of the common stock on a split-adjusted basis, the Company's ability to timely implement the reverse stock split, the Company's belief that the reverse stock split will allow the Company to regain compliance with Nasdaq listing standards, its goal to position the company for long term-growth and value creation, and the potential to achieve that goal, and regarding the future success of its LineaDNA™ and LineaIVT™ platforms. Actual results could differ materially from those projected due to the Company's history of net losses, limited financial resources, substantial doubt regarding its ability to continue as a going concern, unknown future demand for its biotherapeutics products and services, the unknown amount of revenues and profits that will result from our LineaDNA and/or LineaIVT platforms, the fact that there has never been clinical trial material and/or a commercial drug product produced utilizing the LineaDNA and/or LineaIVT platforms, the unknown amount of revenues and profits that will result from its clinical laboratory testing services, as well as various other factors detailed from time to time in Applied DNA's SEC reports and filings, including its Annual Report on Form 10-K filed on December 17, 2024, its Quarterly Reports on Form 10-Q filed on February 13, 2025, and May 15, 2025, and other reports it files with the SEC, which are available at Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law. Applied DNA Sciences Contact: Investor Relations contact: Sanjay M. Hurry, 917-733-5573, Web: ### SOURCE: Applied DNA Sciences, Inc.
Yahoo
21-05-2025
- Business
- Yahoo
Ekso Bionics Announces New Effective Date of Reverse Stock Split
SAN RAFAEL, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the 'Company') (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that it has updated the effective date of its reverse stock split of shares of its common stock at a ratio of 1-for-15 to June 2, 2025 at 12:01 a.m., Pacific time, rather than the previously disclosed effective date of May 27, 2025 at 12:01 a.m. Pacific time. The Company's common stock will open for trading on The Nasdaq Capital Market on June 2, 2025 on a split-adjusted basis under the existing symbol 'EKSO'. The Company's common stock will trade under a new CUSIP number 282644 400 upon the effectiveness of the reverse stock split. Upon the effectiveness of the reverse stock split, the number of shares of the Company's outstanding common stock will decrease from approximately 35.5 million pre-split shares to approximately 2.4 million post-split shares, with no change in par value, per share. The reverse stock split was approved by the Company's stockholders at a special meeting held on May 16, 2025, and is primarily intended to raise the per share trading price of the Company's common stock. As previously reported, the Company received written notice on December 12, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC ('Nasdaq'), informing the Company that it had failed to meet the minimum bid price requirement of the Nasdaq listing rules for The Nasdaq Capital Market. To regain compliance, the closing bid price of the Company's common stock must be at least $1.00 for a minimum of ten consecutive trading days. No fractional shares will be issued as a result of the reverse stock split. Any holder that would otherwise receive a fractional share of common stock as a result from the reverse stock split will have those shares rounded up to the next whole share. The reverse stock split will affect all issued and outstanding shares of the Company's common stock. The reverse stock split will reduce the number of shares of common stock issuable upon the exercise of the Company's then-outstanding stock options or warrants outstanding immediately prior to the reverse stock split and correspondingly increase the respective exercise prices, and it will reduce the number of shares to be received upon vesting of the Company's then-outstanding restricted stock units. The reverse stock split will not be accompanied by a proportional reduction in the number of authorized shares of the Company's common stock. The reverse stock split will affect all stockholders uniformly and will not significantly alter any stockholder's percentage interest in the Company's equity. Stockholders who hold their shares electronically in book-entry form at a brokerage firm or through the Ekso Bionics, Inc. 401(k) plan need not take any action, as their shares will be automatically adjusted by their brokerage firm or trustee of the 401(k) plan, as applicable, to reflect the reverse stock split. Beneficial holders may contact their bank, broker or nominee with any questions regarding the procedure of implementing the reverse stock split. Stockholders holding share certificates may request to receive information from VStock Transfer, LLC, the Company's transfer agent, regarding the process for exchanging the certificated evidencing their shares of common stock for new certificates reflecting the reverse stock split. Additional information regarding the reverse stock split can be found in the Company's Definitive Proxy Statement on Schedule 14A (Form DEF14A), filed with the SEC on April 10, 2025, and posted on the Company's website at About Ekso Bionics Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Based upon its industry-leading expertise, the Company focuses on improving health and quality of life with advanced robotics designed to enhance, amplify, and restore human function. Ekso Bionics is the only known exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol 'EKSO.' For more information, visit: Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding the plans, objectives and expectations of management with respect to the impact of the reverse stock split, including with respect to the Company's ability to regain compliance with the minimum bid price requirement for maintaining its listing on The Nasdaq Capital Market and each stockholder's ownership percentage in the Company following the reverse stock split. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to maintain its listing on The Nasdaq Capital Market, the Company's inability to realize the benefits of the NVIDIA Connect program or successfully complete the building of a proprietary model for human motion, the Company's inability develop and integrate related new AI capabilities across its portfolio, the Company's inability to obtain adequate financing to fund and grow the Company's operations and necessary to develop or enhance the Company's technology, the Company's inability to successfully collaborate with its network of existing neuro-rehabilitation facilities, physicians, and DMEs in seeking CMS reimbursements, the Company's inability to obtain future reimbursements from CMS in a timely manner and at the expected reimbursement levels, the Company's ability to raise funds to operate and grow its business, the Company's inability to obtain insurance coverage beyond CMS, the Company's inability to obtain additional indications of use for its devices, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of the Company's sales and marketing efforts or of partners to market the Company's products effectively, adverse results in future clinical studies of the Company's medical device products, the failure of the Company to obtain or maintain patent protection for the Company's technology, the failure of the Company to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, disruptions in the Company's supply chain, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's most recently filed Annual Report on Form 10-K and its subsequently filed Quarterly Reports on Form 10-Q. To learn more about Ekso Bionics please visit the Company's website at or refer to the Company's X page, formerly Twitter, at @EksoBionics. Any forward-looking statements made in this press release speak only as of the date of this press release. The Company does not undertake to update these forward-looking statements, except as required by law. Contact: Stephen KilmerInvestor RelationsDirect: (646) 274-3580Email: skilmer@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-05-2025
- Business
- Yahoo
ClearOne, Inc. Announces 1-for-15 Reverse Stock Split
SALT LAKE CITY, May 21, 2025--(BUSINESS WIRE)--At a special meeting of stockholders to be held on May 30, 2025 (the "Special Meeting") of ClearOne, Inc. (NASDAQ: CLRO), the Company's stockholders will vote to approve a proposal to authorize a reverse stock split of the Company's issued and outstanding common stock, par value $0.001 per share (the "Common Stock") by a ratio of between 1-for-10 and 1-for-15 (the "Reverse Stock Split Proposal"). Today the Company announced that, subject to stockholder approval of the Reverse Stock Split Proposal at the Special Meeting, the Company will effect a 1-for-15 reverse stock split of the Company's issued and outstanding Common Stock effective at 5:00 p.m. Eastern time on June 2, 2025 (the "Effective Time"). The Company's Common Stock will begin trading on a reverse stock split adjusted basis on The Nasdaq Capital Market at market open on June 3, 2025. The Company's Board of Directors has approved the 1-for-15 reverse split ratio, and upon stockholder approval of the Reverse Stock Split Proposal at the Special Meeting, immediately following the conclusion of the Special Meeting on May 30, 2025, the Company will file certificate of amendment to its Certificate of Incorporation to effect the Reverse Stock Split at the Effective time. The Reverse Stock Split is primarily intended to increase the Company's per share market price of its Common Stock to regain compliance with the minimum per share bid price requirement for continued listing on The Nasdaq Capital Market. The Company's common stock will continue to trade on The Nasdaq Capital Market under the trading symbol "CLRO," but will trade under the following new CUSIP number: 18506U203. As a result of the Reverse Stock Split, every 15 shares of the Company's issued and outstanding Common Stock will be automatically combined into one new share of Common Stock. No fractional shares will be issued in connection with the Reverse Stock Split. Any fraction of a share resulting from the Reverse Stock Split will be converted to one whole share of Common Stock in lieu of such fractional shares. The par value per share of Common Stock will remain unchanged at $0.001. Proportional adjustments will be made to the number of shares of Common Stock issuable upon the exercise of the Company's outstanding stock options and warrants, and the number of shares authorized and reserved for issuance pursuant to the Company's equity incentive plans. The Reverse Stock Split will not alter stockholders' percentage ownership interest in the Company, except to the extent that the Reverse Stock Split results in fractional ownership as described above. The Reverse Stock Split will not change the authorized number of shares of the Company's common stock, and will reduce the number of issued and outstanding shares of the Company's Common Stock from approximately 26.0 million to approximately 1.7 million. The Company's transfer agent, Colonial Stock Transfer, will serve as the exchange agent for the Reverse Stock Split. Registered stockholders holding pre-split shares of the Company's Common Stock electronically in book-entry form are not required to take any action to receive post-split shares. Those stockholders who hold their shares in brokerage accounts or in "street name" will have their positions automatically adjusted to reflect the Reverse Stock Split, subject to each broker's particular processes, and will not be required to take any action in connection with the Reverse Stock Split. Stockholders holding shares of the Company's Common Stock in certificate form will receive a transmittal letter from Colonial Stock Transfer with instructions as soon as practicable after the Effective Time. About ClearOne ClearOne is a global company that designs, develops, and sells conferencing, collaboration, and network streaming solutions for voice and visual communications. The performance and simplicity of its advanced comprehensive solutions offer unprecedented levels of functionality, reliability, and scalability. Visit ClearOne at View source version on Contacts Investor Relations Contact: Simon Brewer385-426-0565investor_relations@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
21-05-2025
- Business
- Business Wire
ClearOne, Inc. Announces 1-for-15 Reverse Stock Split
SALT LAKE CITY--(BUSINESS WIRE)--At a special meeting of stockholders to be held on May 30, 2025 (the 'Special Meeting') of ClearOne, Inc. (NASDAQ: CLRO), the Company's stockholders will vote to approve a proposal to authorize a reverse stock split of the Company's issued and outstanding common stock, par value $0.001 per share (the 'Common Stock') by a ratio of between 1-for-10 and 1-for-15 (the 'Reverse Stock Split Proposal'). Today the Company announced that, subject to stockholder approval of the Reverse Stock Split Proposal at the Special Meeting, the Company will effect a 1-for-15 reverse stock split of the Company's issued and outstanding Common Stock effective at 5:00 p.m. Eastern time on June 2, 2025 (the 'Effective Time'). The Company's Common Stock will begin trading on a reverse stock split adjusted basis on The Nasdaq Capital Market at market open on June 3, 2025. The Company's Board of Directors has approved the 1-for-15 reverse split ratio, and upon stockholder approval of the Reverse Stock Split Proposal at the Special Meeting, immediately following the conclusion of the Special Meeting on May 30, 2025, the Company will file certificate of amendment to its Certificate of Incorporation to effect the Reverse Stock Split at the Effective time. The Reverse Stock Split is primarily intended to increase the Company's per share market price of its Common Stock to regain compliance with the minimum per share bid price requirement for continued listing on The Nasdaq Capital Market. The Company's common stock will continue to trade on The Nasdaq Capital Market under the trading symbol 'CLRO,' but will trade under the following new CUSIP number: 18506U203. As a result of the Reverse Stock Split, every 15 shares of the Company's issued and outstanding Common Stock will be automatically combined into one new share of Common Stock. No fractional shares will be issued in connection with the Reverse Stock Split. Any fraction of a share resulting from the Reverse Stock Split will be converted to one whole share of Common Stock in lieu of such fractional shares. The par value per share of Common Stock will remain unchanged at $0.001. Proportional adjustments will be made to the number of shares of Common Stock issuable upon the exercise of the Company's outstanding stock options and warrants, and the number of shares authorized and reserved for issuance pursuant to the Company's equity incentive plans. The Reverse Stock Split will not alter stockholders' percentage ownership interest in the Company, except to the extent that the Reverse Stock Split results in fractional ownership as described above. The Reverse Stock Split will not change the authorized number of shares of the Company's common stock, and will reduce the number of issued and outstanding shares of the Company's Common Stock from approximately 26.0 million to approximately 1.7 million. The Company's transfer agent, Colonial Stock Transfer, will serve as the exchange agent for the Reverse Stock Split. Registered stockholders holding pre-split shares of the Company's Common Stock electronically in book-entry form are not required to take any action to receive post-split shares. Those stockholders who hold their shares in brokerage accounts or in 'street name' will have their positions automatically adjusted to reflect the Reverse Stock Split, subject to each broker's particular processes, and will not be required to take any action in connection with the Reverse Stock Split. Stockholders holding shares of the Company's Common Stock in certificate form will receive a transmittal letter from Colonial Stock Transfer with instructions as soon as practicable after the Effective Time. About ClearOne ClearOne is a global company that designs, develops, and sells conferencing, collaboration, and network streaming solutions for voice and visual communications. The performance and simplicity of its advanced comprehensive solutions offer unprecedented levels of functionality, reliability, and scalability. Visit ClearOne at
